The Emirates Drug Establishment has approved EURneffy, the first nasal spray in the region developed for the emergency treatment of anaphylaxis. The medication contains epinephrine and is available in 1 mg and 2 mg doses, with administration based on the patient’s weight. It is approved for use in adults and children aged four years and above.
Developed by ALK-Abelló, the treatment introduces a needle-free alternative to traditional injection-based epinephrine. This innovation is expected to significantly improve emergency response, as nasal administration allows for faster and simpler use during critical moments when every second counts.
Timely delivery of epinephrine is essential in preventing life-threatening complications from severe allergic reactions. However, the use of injections can sometimes be delayed due to needle-related fear or difficulty in administering the dose correctly. EURneffy addresses these challenges with a user-friendly design that enables quick action, even by individuals without medical training.
The approval follows collaboration between UAE authorities and the manufacturer to accelerate access to the treatment, reflecting the country’s focus on enhancing healthcare preparedness and patient safety. Officials emphasised that adopting advanced, easy-to-use therapies plays a key role in improving outcomes and reducing risks during emergencies.
This step further strengthens the UAE’s position as a regional leader in healthcare innovation, supported by a regulatory system that balances rapid access to new treatments with strict safety and quality standards, ultimately benefiting public health and quality of life.
Reported by Gold 101.3 FM, UAE’s No.1 Malayalam radio station.
